Technology | Radiation Therapy | October 20, 2017

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance

System provides high-dose treatment for various types of skin cancer

Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance

October 20, 2017 — Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k) clearance for treatment of skin cancer. The Photoelectric Therapy System is a compact and ergonomic superficial X-ray therapy system operating in the 10kV to 80kV range intended for superficial radiotherapy and surface electronic brachytherapy treatment of primary malignant epithelial neoplasms of the skin and keloids.

Utilizing trusted and clinically proven low energy photons in a dedicated treatment system, the Photoelectric Therapy System provides a pain-free, non-surgical alternative for the treatment of non-melanoma skin cancer and superficial lesions, especially those found in sensitive areas of the head and neck.

Using an ideal depth dose profile for the treatment of superficial skin lesions, the high dose output enables treatment times to be kept to a minimum in the same manner as electronic brachytherapy systems while treating a wider range of skin conditions. The low half-value layer (HVL) of the system allows for higher doses without compromising on depth of delivery.

Typical applications include treatment for:

  • Basal cell carcinoma;
  • Squamous cell carcinoma;
  • Metatypic carcinoma;
  • Cutaneous appendage carcinoma;
  • Karposi's sarcoma;
  • Merkel cell carcinoma;
  • Lentigo maligna;
  • Lentigo maligna melanoma;
  • Cutaneous lymphomas (B and T cell); and
  • Keloids.

The system is freestanding, self-contained, unobtrusive, compact and lightweight, which helps to ensure a reassuring and stress-free patient experience in any clinical facility. The system is mounted on lockable castors, allowing free movement and operation in any clinical space. It features ergonomically designed controls ensuring smooth adjustment and safe, simple patient set-up. The system requires connection to the clinical facilities electrical supply and room interlocks, but generates X-rays using a 24V power supply.

Photoelectric therapy devices require minimal shielding as compared to higher energy X-ray therapy systems.

For more information: www.xstrahl.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve